BioSpace News Archive

MaaT Pharma announced on March 28th, 2022, the inclusion of the first patient in a pivotal Phase 3 clinical trial, potentially the last step of clinical development before marketing authorization, evaluating MaaT013 for the treatment of acute gastrointestinal Graft-versus-Host Disease, a serious complication following stem cell transplantation.

Xinvento, a biotech company aiming to improve the lives of those with Congenital Hyperinsulinism, announces the completion of a seed funding round.

Lysogene announced the publication of a peer-reviewed article in EMBO Molecular Medicine e14649) showing that adeno-associated viral vector-delivered diacylglycerol kinase achieves long-term rescue of fragile X syndrome in a mouse model of disease.

Active Biotech entered into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis (Feb 9)

Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, announced its business update and interim report for January to March 2022.

Vicore Pharma Holding AB, a clinical-stage pharmaceutical company, announces the first patient enrolled in the pilot phase of COMPANION1, a clinical study of a digital cognitive behavioral therapy for patients with IPF.

DaVita Inc., announced that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 5, 2022, at 5 p.m. Eastern Time.

It takes years of diligent training as well as a trusting relationship between horse and rider to reach their full potential as a team.

Oncopeptides AB, a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, announces that the 2021 Annual Report has been published.

AlzeCure Pharma AB announced that the company’s presentations at the Alzheimer’s conference 2nd Swedish Meeting for Alzheimer Research, regarding the research platform NeuroRestore and its primary drug candidate ACD856, are now available in their entirety on the company’s website.